世界の心臓安全サービス市場 – 業界動向と2029年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

世界の心臓安全サービス市場 – 業界動向と2029年までの予測

  • Medical Devices
  • Published Report
  • May 2022
  • Global
  • 350 ページ
  • テーブル数: 289
  • 図の数: 64

世界の心臓安全サービス市場、サービス別(ECG/ホルター測定、血圧測定、体外心臓安全評価サービス、心血管画像診断、リアルタイム遠隔測定モニタリング、ECGSの中央オーバーリード、非侵襲性心臓画像診断、生理学的ストレステスト、徹底したQT試験、TQTおよび曝露反応モデリング、血小板凝集およびその他のサービス)、フェーズ別(フェーズ1、フェーズ2、フェーズ3)、タイプ別(統合サービスおよびスタンドアロンサービス)、エンドユーザー別(医薬品およびバイオ医薬品会社、契約研究機関、学術研究機関)業界動向および2029年までの予測。

心臓安全サービス市場

市場分析と洞察

世界の心臓安全サービス市場は、新薬開発の増加、新興企業の増加、技術革新などの要因によって牽引されており、需要が高まり、研究開発への投資も増加しているため、市場の成長につながっています。現在、さまざまな研究調査が行われており、メーカーが新しい革新的な心臓安全サービス システムを開発するための競争上の優位性が生まれ、心臓安全サービス市場にさまざまな機会がもたらされると期待されています。ただし、承認に関する政府の厳しい規制により、成長が妨げられると予想されます。

心臓安全サービス市場

心臓安全サービス市場

心臓安全サービスの世界市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品製品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間における市場の需要を推進した主な原動力です。

世界の心臓安全サービス市場は支援的であり、病気の進行を抑えることを目指しています。データブリッジマーケットリサーチは、世界の心臓安全サービス市場は2022年から2029年の予測期間中に15.4%のCAGRで成長すると分析しています。

レポートメトリック

詳細

予測期間

2022年から2029年

基準年

2021

歴史的な年

2020 (2019 - 2014 にカスタマイズ可能)

定量単位

売上高は百万米ドル、価格は米ドル

対象セグメント

サービス別 (ECG/ホルター測定、血圧測定、体外心臓安全性評価サービス、心血管画像、リアルタイムテレメトリモニタリング、ECGS の中央オーバーリード、非侵襲性心臓画像、生理学的ストレステスト、徹底的な QT 試験、TQT および曝露反応モデリング、血小板凝集およびその他のサービス)、フェーズ別 (フェーズ 1、フェーズ 2、フェーズ 3)、タイプ別 (統合サービスおよびスタンドアロンサービス)、エンドユーザー別 (製薬およびバイオ医薬品会社、契約研究機関、学術研究機関)

対象国

米国、カナダ、メキシコ、ブラジル、アルゼンチンおよびその他の南米、南アフリカ、サウジアラビア、UAE、イスラエル、エジプトおよびその他の中東およびアフリカ、ドイツ、フランス、英国、イタリア、スペイン、トルコ、ロシア、オランダ、スイス、ベルギーおよびその他のヨーロッパ、中国、日本、韓国、インド、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピンおよびその他のアジア太平洋地域

対象となる市場プレーヤー

Koninklijke Philips NV、Laboratory Corporation of America Holdings、IQVIA、Medpace、Ncardia、Certara、Eurofins Scientific、SGS SA、Banook、Celerion、Biotrial、NEXEL Co., Ltd、Richmond Pharmacology、PhysioStim、Shanghai Medicilon Inc、Clario、PPD Inc など。

市場の定義

心臓安全サービスは、一般的に、心臓の安全性を監視するために必要な臨床試験やその他の研究のサポートと設計に役立ちます。心臓安全サービス市場の需要は、先進国と発展途上国の両方で増加しており、その理由は臨床試験と製品発売の増加です。心臓安全サービス市場は、革新的な製品の導入、技術製品の増加、可処分所得の増加により成長しています。市場は、新興市場の探索、市場プレーヤーによる戦略的イニシアチブ、医療費の増加により、予測期間中に成長するでしょう。

世界の心臓安全サービス市場の動向

ドライバー

  • 臨床試験数の増加

臨床試験は、数百年前に遡るよく構造化されたシステムであり、現在でも医薬品の承認に必要な規制要件の根幹となっています。最近、臨床試験の分野では大きな進歩があり、臨床試験の数が増加し、市場の成長を促進することが期待されています。

臨床試験の規制にはさまざまな変更があり、臨床試験の数とその肯定的な結果が増加しました。

例えば、

  • メディカルニュースの記事によると、全職員の研修義務化など臨床試験の質の向上により、試験数が大幅に増加している。また、2017年にNIHは、NIHが資金提供する試験では、すべての研究者と職員が適正臨床試験基準(GCP)の研修を受ける必要があると述べた。

医療費と資金の増加

国が医療に費やす資金の規模と長期にわたる成長率は、資金調達の取り決めや医療制度の組織構造など、さまざまな経済的、社会的要因によって左右されます。

国民の可処分所得の増加に伴い、先進国および新興経済国全体で医療費が増加しています。医療に費やすお金が増えるほど、国の国民はより健康になります。

心臓安全サービス市場

機会

  •  新薬開発の増加

臨床試験は、病気の治療のための新薬の発見と開発に不可欠です。臨床試験は、研究者が人間に効果がある治療法と効果がない治療法を見つけるための最良の方法です。医薬品開発は、がん、内分泌、代謝などのさまざまな病気を治療するための薬やデバイスとして新しい治療法を生み出すことが特徴です。

  • したがって、臨床試験は、市場に投入され、人間が消費する前に治療薬の安全性と有効性を確認する最も効果的な方法であり、これには、あらゆる医療製品が市場に出る前に不可欠な部分である心臓安全性評価が含まれます。

抑制/挑戦

臨床心臓安全性データの適切な評価と報告は不可欠です。あらゆる医療製品の承認と製品回収は心臓安全性評価に依存します。したがって、法的手続きに従って心臓安全性評価を提供および実施する必要があります。そうしないと、製品の承認が遅れ、市場の成長が抑制されることが予想されます。

例えば、

  • IQVIAの記事によると、1957年から2007年の間に47件の医薬品が市販後に回収されたが、そのうち45%は心血管毒性に関する懸念によるものだった。同様に、過去20年間に前臨床段階で失敗した新薬候補分子の27%は、必要な規制要件を満たさなかったため心血管毒性が原因であった。

世界の心臓安全サービス市場のセグメンテーション

世界の心臓安全サービス市場は、タイプ、サービス、フェーズ、エンドユーザーに分類されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。

サービス

  • 心電図/ホルター測定
  • 血圧測定
  • 体外心臓安全性評価サービス
  • 心臓血管画像診断
  • リアルタイムテレメトリモニタリング
  • 心電図の中央オーバーリード
  • 非侵襲性心臓画像診断
  • 生理学的ストレステスト
  • 徹底したQT試験
  • TQTと曝露反応モデリング
  • 血小板凝集
  • その他のサービス

サービスに基づいて、心臓安全サービス市場は、ECG /ホルター測定、血圧測定、in vitro心臓安全評価サービス、心血管画像、リアルタイムテレメトリモニタリング、ECGSの中央オーバーリード、非侵襲性心臓画像、生理学的ストレステスト、徹底的なQT研究、TQTおよび曝露反応モデリング、血小板凝集およびその他のサービスに分類されます。

段階

  • フェーズ1
  • フェーズ2
  • フェーズ3

心臓安全サービス市場は、フェーズに基づいてフェーズ 1、フェーズ 2、フェーズ 3 に分類されます。

タイプ

  • 統合サービス
  • スタンドアロンサービス

タイプに基づいて、心臓安全サービス市場は統合サービスとスタンドアロンサービスに分類されます。

エンドユーザー

  • 医薬品・バイオ医薬品企業
  • 契約研究機関
  • 学術研究機関

心臓安全サービス市場

エンドユーザーに基づいて、心臓安全サービス市場は、製薬およびバイオ医薬品会社、契約研究機関、学術研究機関に分類されます。

心臓安全サービス地域分析/洞察

心臓安全サービスが分析され、上記のようにタイプ、サービス、フェーズ、エンドユーザー別に市場規模の洞察と傾向が提供されます。

心臓安全サービス報告書の対象国は、米国、カナダ、メキシコ、ブラジル、アルゼンチンおよびその他の南米諸国、南アフリカ、サウジアラビア、UAE、イスラエル、エジプトおよびその他の中東およびアフリカ諸国、ドイツ、フランス、英国、イタリア、スペイン、トルコ、ロシア、オランダ、スイス、ベルギーおよびその他のヨーロッパ諸国、中国、日本、韓国、インド、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピンおよびその他のアジア太平洋諸国です。

発展途上地域での技術進歩の加速により、米国が優位に立つことが予想されます。

心臓安全サービス市場

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。   

競争環境と心臓安全サービス分析

世界の心臓安全サービス市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、心臓安全サービス市場に対する会社の重点にのみ関連しています。

この市場の主要企業としては、Koninklijke Philips NV、Laboratory Corporation of America Holdings、IQVIA、Medpace、Ncardia、Certara、Eurofins Scientific、SGS SA、Banook、Celerion、Biotrial、NEXEL Co., Ltd、Richmond Pharmacology、PhysioStim、Shanghai Medicilon Inc、Clario、PPD Inc などが挙げられます。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、グローバル対地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL CARDIAC SAFETY SERVICES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

5.1 INCIDENCE OF ALL BY GENDER

5.2 TREATMENT RATE

5.3 MORTALITY RATE

5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

6 INDUSTRY INSIGHT

6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.2 PATENT ANALYSIS

6.3 PATENT FLOW DIAGRAM

6.4 KEY PATIENT ENROLLMENT STRATEGIES

6.5 PRICING STRATEGY

7 GLOBAL CARDIAC SAFETY SERVICES MARKET: REGULATIONS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS

8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING

8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS

8.1.4 INCREASE IN R&D ACTIVITIES

8.2 RESTRAINTS

8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION

8.2.2 STRICT REGULATORY

8.3 OPPORTUNITIES:

8.3.1 INCREASE IN NEW DRUG DEVELOPMENT

8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES

8.4 CHALLENGES

8.4.1 TIME-CONSUMING PROCEDURE

8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION

9 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES

9.1 OVERVIEW

9.2 ECG/HOLTER MEASUREMENTS

9.3 BLOOD PRESSURE MEASUREMENTS

9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES

9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS

9.4.1.1 1 CONCENTRATIONS

9.4.1.2 4 CONCENTRATIONS

9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA)

9.4.2.1 3 CONCENTRATIONS

9.4.2.2 5 CONCENTRATIONS

9.4.3 IN VITRO HERG ASSAY

9.4.4 OTHERS

9.5 CARDIOVASCULAR IMAGING

9.6 REAL TIME TELEMETRY MONITORING

9.7 CENTRAL OVER-READ OF ECGS

9.8 NON-INVASIVE CARDIAC IMAGING

9.9 PHYSIOLOGIC STRESS TESTING

9.1 THOROUGH QT STUDIES

9.11 TQT AND EXPOSURE RESPONSE MODELLING

9.12 PLATELET AGGREGATION

9.13 OTHERS

10 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE

10.1 OVERVIEW

10.2 PHASE I

10.3 PHASE II

10.4 PHASE III

11 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE

11.1 OVERVIEW

11.2 INTEGRATED SERVICES

11.3 STANDALONE SERVICES

12 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER

12.1 OVERVIEW

12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES

12.3 CONTRACT RESEARCH ORGANIZATIONS

12.4 ACADEMIC AND RESEARCH INSTITUTE

13 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION

13.1 OVERVIEW

13.2 NORTH AMERICA

13.2.1 U.S.

13.2.2 CANADA

13.2.3 MEXICO

13.3 EUROPE

13.3.1 GERMANY

13.3.2 FRANCE

13.3.3 U.K.

13.3.4 ITALY

13.3.5 SPAIN

13.3.6 TURKEY

13.3.7 RUSSIA

13.3.8 NETHERLANDS

13.3.9 SWITZERLAND

13.3.10 BELGIUM

13.3.11 REST OF EUROPE

13.4 ASIA-PACIFIC

13.4.1 CHINA

13.4.2 JAPAN

13.4.3 SOUTH KOREA

13.4.4 INDIA

13.4.5 AUSTRALIA

13.4.6 SINGAPORE

13.4.7 THAILAND

13.4.8 MALAYSIA

13.4.9 INDONESIA

13.4.10 PHILIPPINES

13.4.11 REST OF ASIA-PACIFIC

13.5 SOUTH AMERICA

13.5.1 BRAZIL

13.5.2 ARGENTINA

13.5.3 REST OF SOUTH AMERICA

13.6 MIDDLE EAST AND AFRICA

13.6.1 SOUTH AFRICA

13.6.2 SAUDI ARABIA

13.6.3 U.A.E.

13.6.4 ISRAEL

13.6.5 EGYPT

13.6.6 REST OF MIDDLE EAST AND AFRICA

14 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

14.3 COMPANY SHARE ANALYSIS: EUROPE

14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 COMPANY PROFILE

15.1 EUROFINS SCIENTIFIC

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.1.5.1 AGREEMENTS

15.1.5.2 ACQUISITION

15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC)

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.2.5.1 INVESTMENT

15.3 KONINKLIJKE PHILIPS N.V.

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.3.5.1 ACQUISITION

15.4 IQVIA

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENTS

15.4.5.1 ACQUISITION

15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENTS

15.5.5.1 NEW LABORATORY

15.5.5.2 ACQUISITION

15.6 BANOOK

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.6.3.1 AGREEMENT

15.7 BIOTRIAL

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.7.3.1 NEW CENTER OPENING

15.8 CELERION

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENT

15.8.3.1 NEW CENTER OPENING

15.9 CERTARA

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.9.4.1 CONTRACT

15.9.4.2 ACQUISITION

15.1 CLARIO

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.10.3.1 PRODUCT EXPANSION

15.11 MEDPACE

15.11.1 COMPANY SNAPSHOT

15.11.2 REVENUE ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENTS

15.11.4.1 ACQUISITION

15.12 NCARDIA

15.12.1 COMPANY SNAPSHOT

15.12.2 PRODUCT PORTFOLIO

15.12.3 RECENT DEVELOPMENT

15.12.3.1 PARTNERSHIP

15.13 NEXEL CO., LTD

15.13.1 COMPANY SNAPSHOT

15.13.2 PRODUCT PORTFOLIO

15.13.3 RECENT DEVELOPMENTS

15.13.3.1 JOINT VENTURE

15.13.3.2 PARTNERSHIP

15.14 PHYSIOSTIM

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.14.3.1 PARTNERSHIP

15.15 RICHMOND PHARMACOLOGY

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.15.3.1 EVENT

15.16 SGS SA

15.16.1 COMPANY SNAPSHOT

15.16.2 REVENUE ANALYSIS

15.16.3 PRODUCT PORTFOLIO

15.16.4 RECENT DEVELOPMENT

15.16.4.1 ACQUISITION

15.17 SHANGHAI MEDICILON INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENTS

15.17.3.1 PARTNERSHIP

15.17.3.2 PARTNERSHIP

16 QUESTIONNAIRE

17 RELATED REPORTS

表のリスト

TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE

TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA

TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE)

TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION

TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE

TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS

TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES

TABLE 8 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 9 GLOBAL ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 GLOBAL BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 GLOBAL OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 25 GLOBAL PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 GLOBAL PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 GLOBAL PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 GLOBAL INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 GLOBAL STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 GLOBAL PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 GLOBAL CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 GLOBAL ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 U.S. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 45 U.S. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 46 U.S. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 47 U.S. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 48 U.S. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 49 U.S. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 U.S. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 51 CANADA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 52 CANADA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 53 CANADA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 54 CANADA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 55 CANADA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 56 CANADA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 CANADA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 MEXICO CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 59 MEXICO IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 60 MEXICO HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 61 MEXICO COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 62 MEXICO CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 63 MEXICO CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 MEXICO CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 65 EUROPE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 66 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 67 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 68 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 69 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 70 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 71 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 73 GERMANY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 74 GERMANY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 75 GERMANY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 76 GERMANY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 77 GERMANY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 78 GERMANY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 GERMANY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 80 FRANCE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 81 FRANCE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 82 FRANCE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 83 FRANCE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 84 FRANCE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 85 FRANCE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 FRANCE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 87 U.K. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 88 U.K. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 89 U.K. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 90 U.K. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 91 U.K. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 92 U.K. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 U.K. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 94 ITALY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 95 ITALY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 96 ITALY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 97 ITALY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 98 ITALY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 99 ITALY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 ITALY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 101 SPAIN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 102 SPAIN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 103 SPAIN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 104 SPAIN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 105 SPAIN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 106 SPAIN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 SPAIN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 108 TURKEY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 109 TURKEY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 110 TURKEY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 111 TURKEY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 112 TURKEY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 113 TURKEY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 TURKEY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 115 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 116 RUSSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 117 RUSSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 118 RUSSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 119 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 120 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 122 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 123 NETHERLANDS IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 124 NETHERLANDS HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 125 NETHERLANDS COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 126 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 127 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 129 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 130 SWITZERLAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 131 SWITZERLAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 132 SWITZERLAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 133 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 134 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 135 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 136 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 137 BELGIUM IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 138 BELGIUM HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 139 BELGIUM COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 140 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 141 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 143 REST OF EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 144 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 145 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 146 ASIA-PACIFIC IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 147 ASIA-PACIFIC HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 148 ASIA-PACIFIC COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 149 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 150 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 152 CHINA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 153 CHINA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 154 CHINA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 155 CHINA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 156 CHINA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 157 CHINA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 158 CHINA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 159 JAPAN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 160 JAPAN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 161 JAPAN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 162 JAPAN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 163 JAPAN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 164 JAPAN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 JAPAN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 166 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 167 SOUTH KOREA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 168 SOUTH KOREA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 169 SOUTH KOREA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 170 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 171 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 173 INDIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 174 INDIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 175 INDIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 176 INDIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 177 INDIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 178 INDIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 179 INDIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 180 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 181 AUSTRALIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 182 AUSTRALIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 183 AUSTRALIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 184 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 185 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 187 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 188 SINGAPORE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 189 SINGAPORE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 190 SINGAPORE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 191 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 192 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 193 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 194 THAILAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 195 THAILAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 196 THAILAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 197 THAILAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 198 THAILAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 199 THAILAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 200 THAILAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 201 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 202 MALAYSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 203 MALAYSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 204 MALAYSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 205 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 206 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 207 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 208 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 209 INDONESIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 210 INDONESIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 211 INDONESIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 212 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 213 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 215 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 216 PHILIPPINES IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 217 PHILIPPINES HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 218 PHILIPPINES COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 219 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 220 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 221 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 222 REST OF ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 223 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 224 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 225 SOUTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 226 SOUTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 227 SOUTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 228 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 229 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 230 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 231 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 232 BRAZIL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 233 BRAZIL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 234 BRAZIL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 235 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 236 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 237 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 238 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 239 ARGENTINA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 240 ARGENTINA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 241 ARGENTINA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 242 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 243 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 244 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 245 REST OF SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 246 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 247 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 248 MIDDLE EAST AND AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 249 MIDDLE EAST AND AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 250 MIDDLE EAST AND AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 251 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 252 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 253 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 254 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 255 SOUTH AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 256 SOUTH AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 257 SOUTH AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 258 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 259 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 260 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 261 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 262 SAUDI ARABIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 263 SAUDI ARABIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 264 SAUDI ARABIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 265 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 266 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 267 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 268 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 269 U.A.E. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 270 U.A.E. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 271 U.A.E. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 272 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 273 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 274 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 275 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 276 ISRAEL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 277 ISRAEL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 278 ISRAEL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 279 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 280 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 281 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 282 EGYPT CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 283 EGYPT IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 284 EGYPT HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 285 EGYPT COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 286 EGYPT CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 287 EGYPT CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 288 EGYPT CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 289 REST OF MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

図表一覧

FIGURE 1 GLOBAL CARDIAC SAFETY SERVICES MARKET: SEGMENTATION

FIGURE 2 GLOBAL CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL CARDIAC SAFETY SERVICES MARKET: GLOBAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID

FIGURE 9 GLOBAL CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL CARDIAC SAFETY SERVICES MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE GLOBAL CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029

FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL CARDIAC SAFETY SERVICES MARKET

FIGURE 15 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021

FIGURE 16 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION)

FIGURE 17 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029)

FIGURE 18 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE

FIGURE 19 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021

FIGURE 20 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION)

FIGURE 21 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029)

FIGURE 22 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE

FIGURE 23 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021

FIGURE 24 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 25 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 26 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE

FIGURE 27 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021

FIGURE 28 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 29 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029)

FIGURE 30 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE

FIGURE 31 GLOBAL CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)

FIGURE 32 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2021)

FIGURE 33 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2022 & 2029)

FIGURE 34 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2021 & 2029)

FIGURE 35 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)

FIGURE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)

FIGURE 37 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)

FIGURE 38 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 39 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 40 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)

FIGURE 41 EUROPE CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)

FIGURE 42 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)

FIGURE 43 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 44 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 45 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)

FIGURE 46 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)

FIGURE 47 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)

FIGURE 48 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 49 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 50 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)

FIGURE 51 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)

FIGURE 52 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)

FIGURE 53 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 54 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 55 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)

FIGURE 56 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)

FIGURE 57 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)

FIGURE 58 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 59 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 60 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)

FIGURE 61 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)

FIGURE 62 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)

FIGURE 63 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)

FIGURE 64 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

This cardiac safety services market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market
North America dominates the cardiac safety services market in terms of the most extensive share and revenue generator of the business. That can be credited to the appearance of significant pharmaceutical, drug makers, and bio-pharmaceutical organizations and a considerable amount of clinical analyses conducted in the province.
The major players covered in the cardiac safety services market report are Bioclinica, Laboratory Corporation of America Holdings, ERT, Inc., BioTelemetry, Inc., BANOOK GROUP, IQVIA, Celerion, Certara, L.P., Biotrial, Medpace, Ncardia, Richmond Pharmacology , PPD, Inc . among other domestic and global players.
The major countries covered in the Cardiac Safety Services Market are U.S., Canada, Mexico, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa, Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.